AC Health, the healthcare subsidiary of Ayala Corp., has announced its goal to become a USD2 billion healthcare enterprise by 2035. As it celebrates its 10th anniversary this year, the company is focused on expanding its integrated healthcare ecosystem to serve one in five Filipinos.
AC Health, currently valued at approximately P17 billion—roughly 4 to 5 percent of Ayala Corp.’s P350.46 billion market capitalization—plans to achieve significant growth through both organic and inorganic strategies. The company will continue to expand its network of hospitals, clinics, and retail pharmacies across key cities nationwide.
According to AC Health president and CEO Paolo Borromeo, the company will invest between P1 billion to P2 billion annually, amounting to P6 billion over the next three years, to support its ambitious expansion plans. This investment does not include potential acquisitions, which could be funded independently or through backing from its parent company, Ayala Corp.
“AC Health is building a healthcare group designed for the long haul,” Borromeo said. “We are committed to providing quality, accessible healthcare to every Filipino, backed by a solid ecosystem.”
The company’s planned milestones for the next three years include increasing its retail pharmacy presence to 1,150 locations, expanding its clinic network to 300, and growing its hospital portfolio to 10 facilities. AC Health has already made significant strides since its first investment in Generika Drugstore in 2015, growing into an integrated healthcare provider with 236 corporate and multispecialty clinics, six hospitals under Healthway Medical Network, and 880 pharmacies between Generika and St. Joseph Drug.
In 2024, AC Health reported a 10 percent increase in revenue, totaling P9.4 billion, with its Healthway Medical Network provider group posting an impressive 22 percent revenue growth—well above the industry average of 8 percent. Its pharmaceutical division also outperformed the sector, which saw a 5 percent decline.
As AC Health continues its expansion, its commitment to building a financially resilient and transformative healthcare company remains at the forefront of its strategy, with the goal of becoming a leader in the Filipino healthcare landscape by 2035.
